US 7,498,030 B2
	Treatment with anti-ErbB2 antibodies and anti-hormonal compounds
Camellia W. Adams, Mountain View, Calif. (US); Leonard G. Presta, San Francisco, Calif. (US); and Mark Sliwkowski, San Carlos, Calif. (US)
Assigned to Genetech, Inc., South San Francisco, Calif. (US)
Filed on Sep. 09, 2005, as Appl. No. 11/222,587.
Application 11/222587 is a division of application No. 09/602812, filed on Jun. 23, 2000, granted, now 6,949,245.
Claims priority of provisional application 60/141316, filed on Jun. 25, 1999.
Prior Publication US 2006/0073143 A1, Apr. 06, 2006
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)

U.S. Cl. 424—143.1  [424/130.1; 424/133.1; 424/135.1; 424/138.1; 424/141.1; 424/142.1; 424/152.1; 424/155.1; 424/172.1; 424/174.1; 424/178.1]

14 Claims

1. A method of treating ErbB2-expressing cancer in a human, comprising administering to the human therapeutically effective amounts of (a) an antibody which binds ErbB2 and comprises the variable light (VL) domain amino acid sequence of SEQ ID NO: 3 and the variable (VH) domain amino acid sequence of SEQ ID NO: 4; and (b) an anti-estrogen compound that regulates or inhibits estrogen action on tumors.